U.S. allows ADHD drugmaker to increase production limit to ease shortage
The Drug Enforcement Administration has increased the production limit for Takeda Pharmaceutical’s ADHD drug Vyvanse and its generic versions to ease shortages.
The Drug Enforcement Administration has increased the production limit for Takeda Pharmaceutical’s ADHD drug Vyvanse and its generic versions by about 24% to address the medicine’s ongoing shortage in the United States.
The raised production limit follows the Food and Drug Administration’s request in July, the DEA said in a notice on Tuesday.
ADHD drugs have been in short supply for years. The FDA warned of a shortage of Israel-based drugmaker Teva Pharmaceutical Industries’ Adderall in October 2022, troubled by manufacturing delays.
That led to a spike in demand and subsequent shortage of Takeda’s Vyvanse.
Vyvanse, also known as lisdexamfetamine, is classified by the DEA as a schedule II controlled substance, which is applied to drugs considered to have a high likelihood of being abused, and additional prescribing safeguards are put in place.
Rating: 5